Treatment

Placebo to keytruda - Normal saline solution clinical trials

3 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).
This study is testing a new medicine called Keytruda after surgery and radiation for advanced skin cancer (cutaneous squamous cell carcinoma). We want to see if it stops the cancer from coming back compared to a dummy treatment.
For: Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC)
Germany · France · Spain
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
This study is looking at a new way to treat early-stage lung cancer that hasn't spread. It combines a type of radiation called SBRT with a drug called Keytruda or a dummy drug to see if it works better and improves how long people live without their cancer getting worse.
For: Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
Germany · Netherlands · Norway
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
This study is testing if adding a new drug, pembrolizumab (Keytruda), to standard chemotherapy before and after surgery can help people with a type of bladder cancer. Researchers want to see if this combination works better than chemotherapy alone to keep the cancer away.
For: Cis-eligible Muscle-invasive bladder cancer.
Hungary · Belgium · Germany

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)